Common bacteria cause some colon tumors by altering peroxide-producing gene

"Our data suggest that the SMO gene and its products may be one of the few good targets we have discovered for chemoprevention," says Robert Casero, Ph.D., professor of oncology at the Johns Hopkins Kimmel Cancer Center.

In a study, Casero and his colleagues introduced B. fragilis to two colon cell lines and measured SMO gene activity. In both cell lines, SMO gene activity increased two to four times higher than cells not exposed to the bacteria. The scientists also observed similar increases in enzymes produced by the SMO gene. The scientists successfully prevented DNA damage in these cells by blocking SMO enzyme activity with a compound called MDL 72527.

The Johns Hopkins team also tested their observations in a mouse model, created by Hopkins infectious disease specialist Cynthia Sears, M.D., to develop colon tumors. Mice exposed to the bacteria had similar increases in SMO. Mice treated with MDL 72527 had far fewer tumors and lower levels of colon inflammation than untreated mice. Results of the experiments were published online in the Proceedings of the National Academy of Sciences in August.

Casero says hydrogen peroxide can freely distribute through and into other cells. "It roams around, and can damage the DNA in cells," he says.

Rising levels of hydrogen peroxide and DNA damage in the colon are clear steps to tumor development, says Andrew Goodwin, Ph.D., who spearheaded the studies while performing graduate work in Johns Hopkins' Cellular and Molecular Medicine Program and Casero's laboratory.

B. fragilis strains that secrete a toxin are widely known to cause diarrhea in children and adults, and previous studies, including those at Johns Hopkins, have linked the toxin-producing bacteria to inflammation and colon cancer. Casero and collaborators previously linked the SMO gene to inflammation and cancer of the prostate and stomach.

Using MDL 72527 in humans is not advised, Casero says, because the compound blocks another enzyme in addition to SMO. Investigators hope to develop a drug that targets only the SMO enzyme. Candidates for such prevention strategies may include people with a history of colon polyps, which increases risk for colon cancer, and those with inflammatory bowel disease.

Provided by Johns Hopkins Medical Institutions